Advances in the management of peritoneal mesothelioma

Table 1 Selected studies examining overall survival with cytoreduction and hyperthermic intraperitoneal chemotherapy

Ref.	Year	Era	Sample No.	Age	Gender (female)	HIPEC Agents	Histological Subtype or Grade	Follow-up	Median survival	1 yr	2 yr	3 yr	5 yr	7 yr	10 yr
Park et al[33]	1999	1993-1998	18	47	28%	CDDP	9 E, 3 mixed 1 MMF 1 cystic 4 Unk	19	NR		80
Loggie et al[112]	2001		12	511	8%	MMC	Not stated	45.2	34.2	60	60	50	33	33
Feldman et al[48]	2003	1993-2002	49	47	43%	CDDP	26 E, 4 S 16 TP 1 adenomatoid	28.3	92	86	77	59	59
Costamagna et al[61]	2003	1995-2003	24			CDDP + DOXO, single agent MMC or DOXO			40	78	70	70	52
Brigand et al[6]	2006	1989-2004	15	53.6	29%	CDDP + MMC	12 E, 2 B 1 MC	46.7	35.6	69.3	57.7	43.3	28.9
Elias et al[60]	2007	1996-2005	26	461	46%	oxaliplatin + irinotecan, single agent oxaliplatin or DOXO	13 E, 1 B 11 TP, 1 MC	55	100	88	83	68	63
Gómez Portilla et al[113]	2007	1998-2005	7	501	43%	CDDP + DOXO, single agent MMC or oxaliplatin	5 E, 2 B	11	NR	43	43	43	43
Hesdorffer et al[55]	2008	1997-2000	27	531	26%	CDDP + MMC	23 E, 4 S		70			67%
Passot et al[114]	2008	1989-2006	22			CDDP + MMC	16 E, 3 B 3 MC	47	36.9	69	62	52	31
Chua et al[115]	2009	1997-2008	20	55.71	30%	CDDP + DOXO	16 E, 1 B, 2 S 1 MC	18.1	29.5	78.2		46.3
Blackham et al[49]	2010	1993-2008	34	54.91	32%	CDDP or MMC	29 E, 4 B 1 Unk	72	40.8	61		56	17
Kluger et al[54]	2010	1997-2004	47	491	36%	CDDP + MMC	43 E, 4 B	54	54.9	80.9		61.7	48.9
Cao et al[46]	2012	1989-2009	294	50	46%	CDDP + DOXO2	259 E, 27 B/S 8 Unk	25	67	83	62	52
Alexander et al[47]	2013	1992-2010	211	52	60%	CDDP or MMC	113 High, 54 Low 44 Unk		38.4				41		26
Schaub et al[59]	2013	1994-2010	104	50.9	39%	CDDP	90 E, 14B/S	49.4	52			58	46
Wong et al[52]	2013	2004-2012	26	64	38%	CDDP	15 E, 3 B 1 MMF 3 WD, 1 cystic 3 Unk		41.2
NMDeraco et al[37]	2003	1995-2002	19	491	53%	CDDP + MMC or DOXO	13 E, 1 S, 1 mixed 2WD, 2MC	27	NR			69
NMDeraco et al[39]	2003		28		61%								70
NMDeraco et al[38]	2003		61	511	49%	CDDP + MMC or DOXO		20					54
NMDeraco et al[40]	2006	1995-2005	49	521		CDDP + DOXO or MMC	43 E, 6 B	20.31					57
NMDeraco et al[50]	2013	1995-2011	116	54.41	48%	CDDP + DOXO or MMC	105 E, 11 B/S	32.91					49
NMBaratti et al[20]	2007	1997-2005	60	53.5	60%		43 E, 6 B 5 MC, 6 P	23					53.7
NMBaratti et al[36]	2007	1995-2006	12	38	100%	CDDP + DOXO	4 MC, 8 WD	27	NR				90
NMBaratti et al[35]	2010	1996-2008	83	54	55%	CDDP + MMC or DOXO	72 E, 10 B, 1 S	52	44				49.5		45.5
NMBaratti et al[34]	2013	1996-2012	108	56.5	46%	CDDP + DOXO or MMC	93 E, 14 B, 1 S	48.8	63.2				52.4		44.6
WCYan et al[45]	2006		100	501	40%	CDDP + DOXO	86 E, 7 B/S 7 Unk	48	52	78		55	46	39
WCYan et al[44]	2007	1989-2005	70	471	43%	CDDP + DOXO	65 E, 5 B	35	59	82	67	57	49
WCYan et al[41]	2007	1989-2005	62	471	45%	CDDP + DOXO	57 E, 5 B	37	79	84		58	50
WCYan et al[42]	2009	1989-2009	401	501	44%	CDDP + DOXO2 or MMC, single agent CDDP or MMC	318 E, 48 B/S 35 Unk	33	53	81		60	47
WCYan et al[43]	2011	1989-2009	294	501	46%	CDDP + DOXO2	259 E, 27 B/S 8 Unk	24	67	83	62	52

¹Mean values are indicated with an asterisk. Follow-up and survival are reported in months;

²Most common chemotherapy agent reported. The principal centers including the National Cancer Institute of Milan and the Washington Cancer Center are noted with superscripts NM and WC, respectively. NR: Not reached; CDDP: Cisplatin; MMC: Mitomycin or Mitomycin C; DOXO: Doxorubicin; E: Epithelial or epithelioid subtype; B: Biphasic; S: Sarcomatoid or sarcomatous; B/S: Biphasic or sarcomatoid; MMF: Malignant or epithelial with mucinous features; MC: Benign multicystic; TP: Tubillopapillary; P: Papillary or mixed papillary; WD: Well-differentiated; Unk: Unknown or not specified.